Contact Details:
Mike Seed graduated in Pharmacology, with a PhD from the University of Bath, followed by a lectureship. He joined the pharmaceutical industry in arthritis Drug Discovery in arthritis and angiogenesis disease modelling, drug screening and target validation, centring on leflunomide analogues, phospholipase A2 and matrix metalloproteinase inhibitors. He continued his development of inflammatory and cancer disease models, concentrating on transdermal drug delivery, joint destruction, and angiogenesis in the Department of Experimental Pathology, Saint Bartholomew’s Medical College, as an Honorary Senior Lecturer. He is the William Harvey Inflammation Research Fellow and Sir Halley Stewart Trust Lecturer lecturing in inflammopharmacology and drug discovery in the Centre for Experimental Medicine and Rheumatology. He is the BIRAs appointed representative on the Board of the International Association of Inflammation Societies.
Current research interests
Auto-immune diseases, including rheumatoid arthritis, are crippling, very painful and lead to an early death. Dr Seed’s research focuses on the discovery and proof of concept of molecular targets amenable to orally active low molecular weight new chemical entities. These are the next generation of anti-autoimmune therapeutics aimed to replace current biologic treatments. Research centres on in vitro and in vivo modelling and molecular analysis of immune and auto-immune disease mechanisms and the associated tissue destruction. A partnership in the KINACEPT EUFP7 programme is investigating the genetic basis of inter-patient variability in p38MAP-kinase inhibitor responses, the anti-rheumatic potential for p38 inhibitors being largely unfulfilled in the clinic. A collaboration with the University of Manchester on the Wellcome Trust Seeding Drug Discovery Initiative ‘Selective glucocorticoid receptor agonists for the treatment of inflammatory conditions’ is designing novel anti-rheumatic steroids whose anti-inflammatory properties are dissociated from the life-threatening side effects associated with this drug class. This research adds in silico drug design, chemical synthesis, and gene trans-activation and trans- repression screening in the collaboration, to this laboratory which will differentiate the anti-rheumatic activity of dissociated steroids from their osteopenic and diabetic side effects. The mechanistic studies of a novel set of orally active anti-rheumatic and anti-erosive heparinoid-like NCEs invented here, that modulate inflammatory cell adhesion responses and cytokine synthesis profiles, as well as HSV/HIV immune cell interactions are being pursued. PI3kinase is a major interest, funded through the William Harvey Research Foundation. The Gordon van Armand Prize research into the role of IKKα in type IV hypersensitivity responses, and dendritic cell – T cell interactions is being finalised.
Key publications
-
Cyclooxygenase enzymes and their products in the carrageenan-induced pleurisy in rats. Moore AR, Ayoub SS, Seed MP. Methods Mol Biol. 2010;644:201-5 . :http://www.springerlink.com/content/m4w33234n23527n6/
- Cyclo-oxygenases: Methods and Protocols (Book). Eds Ayoub S, Flower RJ, Seed M 2010. Humana Press 2010. LINK http://www.springerprotocols.com/BookToc/doi/10.1007/978-1-59745-364-6
- Animal Models of Rheumatoid Arthritis. Patel HB, Dawson B, Humby F, Blades M, Pitzalis C, Burnet M, Seed M. Fundamentals of Inflammation. Eds Gilroy D & Serhan C. 2010. Cambridge University Press. pp: 384-441. LINK: http://www.cambridge.org/gb/knowledge/isbn/item2709950/?site_locale=en_GB
- Cyclo-oxygenases: Methods and Protocols (Book). Eds Ayoub S, Flower RJ, Seed M 2010. Humana Press 2010. LINK http://www.springerprotocols.com/BookToc/doi/10.1007/978-1-59745-364-6
-
Cyclo-oxygenases: Methods and Protocols (Book). Eds Ayoub S, Flower RJ, Seed M 2010. Humana Press 2010. LINK http://www.springerprotocols.com/BookToc/doi/10.1007/978-1-59745-364-6
-
Human single chain fragment variable (scFv) that specifically targets arthritic cartilage Hughes C., Faurholm B., Dell'Accio F, Manzo A, Seed M, Eltawil N, Marrelli A., Gould D., Subang C., Al-Kashi A., De Bari C., Winyard P., Chernajovsky Y., Nissim A. Arthritis & Rheumatism Epub: DOI 10.1002/art.27346.
http://www3.interscience.wiley.com/cgi-bin/fulltext/123267002/PDFSTART
-
Activation of macrophage peroxisome proliferator-activated receptor-c by diclofenac results in the induction of cyclooxygenase-2 protein and the synthesis of anti-inflammatory cytokines. Ayoub SS, Botting RM, Joshi AN, Seed MP, Colville-Nash PR. Mol. Cell Biochem. 2009. 327:101-110.
http://www.springerlink.com/content/903348jt8248v238/
Development of disease-modifying treatments for rheumatoid arthritis. Seed MP. Pharmaceutical Journal 2009. 282:191-2.
- Angiogenesis in inflammation: mechanisms and clinical correlates. Seed MP, Walsh DA.
-
Study of a combined percutaneous local anaesthetic and the TDS system for venepuncture. Tucker AT, Chik Z, Michaels L, Seed MP, Johnston A, and Alam CAS (2006). Anaesthesia, 2006, 61, pages 123–126.
-
The modulation of intra-articular inflammation, cartilage matrix and bone loss in mono-articular arthritis induced by heat-killed Myobacterium tuberculosis.M.P. Seed, C. R. Gardner (2005). Inflammopharmacology 12(5-6) 551-567.
-
Heat shock proteins and their role in chondrocyte protection, an application for autologous transplantation. D. A. Sawatzky, R. Foster, M.P. Seed, D. A. Willoughby (2005). Inflammopharmacology 12(5-6), 569-589.
- The assessment of inflammation, cartilage matrix and bone loss in experimental mono-articular arthritis in the rat. Seed MP, (2003) Methods Mol Biol 225: 161-174.
-
The effects of cyclooxygenase-2 inhibitors on cartilage erosion and bone loss in a model of mycobacterium tuberculosis-induced monoarticular arthritis in the rat. Gilroy D, Tomlinson A, Greenslade K, Seed MP, Willoughby DA (1998). Inflammation 22:509-519
-
The codependence of angiogenesis and inflammation. Jackson J, Winkler J, Seed MP, Willoughby DA (1997). FASEB J 11:457-465.
-
The Pharmacological modulation of angiogenesis in chronic granulomatous inflammation. Colville-Nash PR, Alam CAS, Appleton I, Brown JR, Seed MP, Willoughby DA (1995). J Pharmacol Exp Ther 274:1463-1472.



